Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Cullinan Therapeutics Presents Preclinical Data for CLN-978 Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will present new preclinical data for CLN-978 at the American College of Rheumatology…